

# Lorenzo Gaetani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9080707/publications.pdf>

Version: 2024-02-01

45  
papers

1,951  
citations

393982

19  
h-index

276539

41  
g-index

46  
all docs

46  
docs citations

46  
times ranked

3126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurofilament light chain as a biomarker in neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 870-881.	0.9	623
2	CSF and blood biomarkers for Parkinson's disease. <i>Lancet Neurology</i> , The, 2019, 18, 573-586.	4.9	393
3	A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 8.	3.0	111
4	Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 3848-3857.	3.3	58
5	CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 1023-1037.	4.0	48
6	Î±-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies. <i>Neurology</i> , 2022, 99, 195-205.	1.5	45
7	Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 2157-2163.	1.8	41
8	Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. <i>Cell Reports</i> , 2021, 37, 110094.	2.9	38
9	2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. <i>Journal of Neurology</i> , 2018, 265, 2684-2687.	1.8	35
10	Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020, 11, 157.	2.2	35
11	Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics. <i>Cells</i> , 2021, 10, 1930.	1.8	34
12	Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 339, 577108.	1.1	31
13	Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. <i>Brain Research</i> , 2015, 1621, 205-213.	1.1	30
14	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. <i>Movement Disorders</i> , 2022, 37, 669-683.	2.2	30
15	The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer's Disease, Parkinson's Disease and Multiple Sclerosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4958.	1.8	28
16	Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica. <i>Neurology</i> , 2012, 79, 1182-1184.	1.5	27
17	Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis. <i>Neurobiology of Disease</i> , 2018, 113, 97-108.	2.1	27
18	The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. <i>Biomolecules</i> , 2020, 10, 335.	1.8	25

#	ARTICLE	IF	CITATIONS
19	Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. <i>Neural Regeneration Research</i> , 2021, 16, 36.	1.6	23
20	Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 35, 228-232.	0.9	20
21	Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms. <i>Journal of Neuroinflammation</i> , 2021, 18, 259.	3.1	20
22	Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2017, 2, .	1.1	19
23	Cerebrospinal fluid and serum d-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2020, 1868, 140537.	1.1	19
24	Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain. <i>Frontiers in Neuroscience</i> , 2021, 15, 672954.	1.4	19
25	Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis. <i>European Journal of Neurology</i> , 2014, 21, 648-653.	1.7	17
26	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders. <i>Frontiers in Neuroscience</i> , 2021, 15, 647783.	1.4	17
27	Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4440.	1.8	17
28	Synaptic Dysfunction in Multiple Sclerosis: A Red Thread from Inflammation to Network Disconnection. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9753.	1.8	17
29	High performance liquid chromatography determination of l-glutamate, l-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease. <i>Amino Acids</i> , 2021, 53, 435-449.	1.2	14
30	Retinopathy during interferon- $\beta$ treatment for multiple sclerosis: case report and review of the literature. <i>Journal of Neurology</i> , 2016, 263, 422-427.	1.8	12
31	High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline. <i>Journal of the Neurological Sciences</i> , 2017, 379, 236-240.	0.3	12
32	Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.	1.7	12
33	Serum neurofilament light chain as a preclinical marker of neurodegeneration. <i>Lancet Neurology</i> , 2019, 18, 1070-1071.	4.9	9
34	Infliximab monotherapy for neuro-Behçet's disease: A case report. <i>Journal of the Neurological Sciences</i> , 2014, 347, 389-390.	0.3	8
35	The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI. <i>Journal of Neurology</i> , 2022, 269, 3129-3135.	1.8	6
36	NfL as Analogue of C-Reactive Protein in Neurologic Diseases. <i>Neurology</i> , 2022, 98, 911-912.	1.5	6

#	ARTICLE	IF	CITATIONS
37	Visual pathway involvement in multiple sclerosis: Look straight in the eyes. <i>Multiple Sclerosis and Related Disorders</i> , 2017, 17, 217-219.	0.9	5
38	Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes. <i>Journal of Neurology</i> , 2018, 265, 522-529.	1.8	5
39	Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency. <i>European Neurology</i> , 2016, 76, 62-68.	0.6	4
40	Finding a way to preserve mitochondria: new pathogenic pathways in experimental multiple sclerosis. <i>Neural Regeneration Research</i> , 2019, 14, 77.	1.6	4
41	Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion. <i>Journal of Neurology</i> , 2016, 263, 1449-1451.	1.8	2
42	Molecular profiling in Parkinsonian syndromes: CSF biomarkers. <i>Clinica Chimica Acta</i> , 2020, 506, 55-66.	0.5	2
43	A blood test for Alzheimer's disease: a step forward. <i>Lancet Neurology</i> , The, 2021, 20, 691-693.	4.9	1
44	Blood biomarkers may distinguish among dementia disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 571-571.	0.9	1
45	Phosphatidylethanolamine Binding Protein (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	1.2	1